Background: Background: Facial paralysis is the most common cranial nerve injury. Bell's palsy is the name commonly used to describe an acute peripheral facial paralysis of unknown origin. The annual incidence of Bell's palsy is 20-30 cases per 100,000 persons, regardless of age and gender.
www.painphysicianjournal.com compare 2 or 3 therapies. Additionally, small sample sizes have prevented these studies from achieving conclusive results, and some studies have produced inconsistent results (6, 7) . Therefore, the best therapy for the treatment of Bell's palsy remains unclear, and a comprehensive comparison of the efficacies of these therapies is needed. In this study, a systematic review and a network meta-analysis (NMA), which integrates the evidence from direct and indirect comparisons, were performed to compare the overall recovery rates associated with 1 to 12 months of steroid drugs, antiviral agents, or the combination of both for the treatment of Bell's palsy. This study offers a complete overview of the effectiveness of current therapies and can be used as a reference by physicians engaged in clinical practice.
Methods

Search Strategy and Study Selection
We performed a systematic search in the Embase and PubMed databases from inception to 2016 without any restrictions on language or type of publication. The following keywords and subject terms were used in the search: "facial paralysis," "Bell´s palsy," "steroid," "corticosteroids," "prednisolone," "antiviral drugs," "acyclovir," and "valacyclovir."
Studies that met the following selection criteria were included: (1) those with patients who were treated for facial paralysis diseases caused by Bell´s palsy; (2) RCTs with at least a 1-month follow-up period; (3) comparisons of the efficacy between placebo and antiviral or steroid treatments; and (4) studies in which the mean age of patients was over 18 years. Studies were excluded if they (1) did not have sufficient data related to this study; (2) did not have relevant outcomes; or (3) included patients who were diagnosed with Ramsay Hunt syndrome.
Outcome Measures and Data Extraction
Overall recovery was chosen as the indicator of efficacy, representing the number of patients who recovered after receiving the relevant treatments. The following information from each study was extracted: first author; publication year; number of patients treated with steroids, antiviral drugs, or combination treatment and placebo; basic patient characteristics (average age, gender); length of the follow-up period; and efficacy outcome. These data are presented in Table 1 . Two independent reviewers extracted the data from original studies, and any discrepancy between the 2 F acial paralysis is the most common cranial nerve injury. Bell's palsy is the name commonly used to describe an acute peripheral facial paralysis of unknown origin. The annual incidence of Bell's palsy is 20-30 cases per 100,000 persons, regardless of age and gender. The reactivation of the herpes simplex virus has been widely recognized as the main cause of Bell's palsy, but this has not been proven (1) . In addition, other viruses -such as herpes zoster virus, human immunodeficiency virus, Epstein Barr Virus, and hepatitis B virus -might be associated with the occurrence of Bell's palsy. In terms of the main clinical symptoms of Bell's palsy, facial asymmetry and facial motor dysfunction can cause dysfunction of the muscles on one side of the face, which, in turn, can cause remarkable disruption in patients' social lives. The underlying mechanism of Bell's palsy is not completely understood, and the cure for this disease is complicated. According to previous studies, 70% of patients experience complete recovery within 6 months of treatment; up to 30% of patients, however, do not recover completely and remain afflicted by residual symptoms such as paresis, synkinesis, and facial spasms (2) .
Two main pharmacological treatments have been used to improve the recovery of Bell's palsy: steroids and antivirals. These treatments target the presumed pathogenetic mechanisms underlying the facial paralysis associated with Bell's palsy: inflammation and viral infection (3) . Steroids, including prednisolone, betamethasone, hydrocortisone, methylprednisolone, dexamethasone, and cortisone, are a group of agents that can effectively decrease inflammation and swelling of the facial nerve. Therefore, they have been used to treat Bell's palsy for decades and continue to be widely used in the early stages of treatment. Antivirals -in particular, acyclovir, famciclovir, and valacyclovirhave also been used to treat Bell's palsy because of the suspicion that, in most patients, Bell's palsy is caused by the herpes simplex virus. The efficacy of antivirals in treating facial paralysis has not yet been validated, but they have gained popularity since the herpes simplex virus was found in patients' saliva and facial nerve endoneurial fluid (4). Combination therapy (antivirals and steroids), which takes advantage of the virtues of both antivirals and steroids, has been suggested as an effective treatment for Bell's palsy (5) .
Some placebo-controlled and head-to-head studies have been conducted to compare the different therapies for Bell's palsy, as shown in the studies cited previously, but randomized clinical trials (RCTs) can only Treatments for Facial Paralysis from Bell´s Palsy 
Statistical Analyses
First, a pairwise meta-analysis was performed to compare the efficacies of treatments that had been directly compare, using a fixed-effects model. The heterogeneity of the included pairwise comparisons was analyzed using Cochran's Q formula and Higgins' I 2 statistic. A P value < 0.05 indicated that there was heterogeneity, which required a random-effects model.
Next, we conducted an NMA based on a Bayesian framework. Overall recovery is represented by an odds ratio (OR) and a corresponding 95% confidence interval (CI). Generally, a 95% CI that excludes one represents a statistically significant result. Cumulative ranking probability plots have been suggested as a comprehensive and reliable way to present ranking probabilities graphically (8) . A rankogram for a specific treatment is a graphical plot of the probabilities associated with all possible ranks (where the total number of positions in the ranking is equal to the total number of treatments in the network); this is slightly different from an absolute rankogram. The surface under the cumulative ranking curve (SUCRA) is used to present the probability of each treatment's ranking and thereby determine the best one. A higher SUCRA value represents better performance on a certain outcome measure. Furthermore, the consistency of a result was evaluated using the node-splitting method. A P value > 0.05 suggests that the study's assumption of consistency was satisfactory. A net heat plot was used to draw patterns and provide more information on the consistency of the network comparison. The R 3.3.3 and WinBUGS (version 1.4.3) software packages were used to conduct all of the above analyses for this study.
Results
Included Articles
As shown in the flow chart ( Fig. 1) , 179 studies were retrieved from the electronic databases. After removing 134 irrelevant articles and duplicates, 45 studies were determined to be eligible. Twenty-two studies were discarded according to the selection criteria. Ultimately, 23 studies were involved in our NMA.
Main Characteristics of the Included Articles
A total of 23 articles were eligible for our study, and the primary characteristics of each trial are shown in Table 1 (1,9-30). All 3 treatments (antiviral, steroid, and antiviral plus steroid) were included among these Treatments for Facial Paralysis from Bell´s Palsy studies. Antiviral drugs mainly include acyclovir, famciclovir, and valacyclovir; steroids include prednisolone, cortisone, betamethasone, hydrocortisone, deflazacort, and methylprednisolone. Among the 23 included studies, 11 RCTs were double-blind, 4 were single-blind, and 8 did not specify type of trial with regard to blinding. The total number of patients was 4,623, and the followup time ranged from 1 to 12 months. The comparisons and the number of studies in each pair are graphed in Fig. 2 .
Pairwise and Network Meta-Analysis Results
As shown in Table 2 , no significant differences were observed among all direct comparisons with respect to overall recovery. However, in terms of ORs, combination treatment (antiviral plus steroid) had a tendency toward higher overall recovery. Figure 3 shows the network comparison results. Compared with placebo therapy, combination treatment (antiviral + steroid) resulted in 3.25 higher odds of OR value (95% CI, 1.23-8.61). Other pairs of comparisons indicated no statistically significant differences between the treatments.
Cumulative Ranking Probability
The analyzed probability of ranking with respect to overall recovery is presented by the SUCRA, as shown in Table 3 and Fig. 4 . With a SUCRA value of 0.96, combination treatment showed the best efficacy and had the highest probability of ranking first (90%). Steroids and antiviral drugs had similar SUCRA values (0.54 and 0.36, respectively), but they were prone to be in second and third place, respectively (59% and 36% for rank probability). Placebo treatment had the worst efficacy, with a SUCRA value of 0.13 and a high probability of being the last choice of treatment (66% probability of ranking in last place).
Consistency Assessment
An assessment of the consistency between the di- www.painphysicianjournal.com rect and indirect sources of evidence was conducted by the splitting node method and P value measurements (Fig. S1) . No significant differences were found between the direct and indirect sources of evidence comparing any 2 treatments; all P values > 0.05. Moreover, a heat map (Fig. 5 ) was used to show the consistency of the results of the NMA. The contribution of direct evidence is represented by the gray squares. The conclusion was almost the same as the result from the node-splitting graph: there were no significant inconsistencies between direct and indirect sources of evidence for any treatment comparisons.
Publication Bias
The funnel plot is used to test for publication bias. One dot represents an included study. No distinct asymmetry pattern was found in the comparison-adjusted funnel graph presented in Fig. S2 . Consequently, there is no evidence of publication bias in our study.
discussion
Facial paralysis from Bell's palsy severely threatens the outward appearance and mental health of patients. In recent years, Bell's palsy has aroused the interest of many researchers, and many studies have been carried out to evaluate the efficacy of different therapies in treating facial paralysis (4, 31, 32) . In this study, an NMA was launched to comprehensively assess the performance of 3 therapies (antiviral, steroid, and antiviral + steroid) for the treatment of Bell's palsy. The results of the proposed NMA indicate that antiviral + steroid treatment is superior to the other 2 therapies with Treatments for Facial Paralysis from Bell´s Palsy respect to overall recovery, and that the efficacies of antiviral or steroid treatments alone are nearly equal. In addition, the SUCRA values indicate that all 3 therapies are better than placebo treatment. Some pairwise meta-analyses have been conducted in previous studies comparing treatments for Bell's palsy, resulting in some contradictory conclusions with respect to the efficacies of different treatments for overall recovery. For instance, Salinas et al compared the efficacies of steroids vs placebo therapy for the treatment of Bell's palsy in terms of overall recovery, and argued that steroids did not show a significant benefit over placebo (7) ; in contrast, Ramsey et al reported that steroids were more effective than placebo (33) . This divergence will cause a dilemma among patients and clinicians. Lockhart et al conducted a meta-analysis to evaluate the efficacy of antiviral agents for the treatment of Bell's palsy and concluded that there was no significant difference between antiviral and placebo treatments with respect to overall recovery (6) . Most of these meta-analyses were placebo-controlled comparisons and did not provide relative rankings for all therapies. Through this study, our NMA has overcome the limitations of previous meta-analyses. First, by organizing all therapies into a network comparison, a relative ranking of all therapies can be easily obtained from the SUCRA values. Meanwhile, the abovementioned contradictions can be eliminated by simultaneously considering direct and indirect sources of evidence.
In this NMA, we used overall recovery as the efficacy outcome to assess 3 treatments for Bell's palsy (antiviral, steroid, and antiviral + steroid). Overall, the www.painphysicianjournal.com results of our NMA were consistent with those of previous works. We found that antiviral + steroid treatment outperformed placebo, consistent with the study of Salinas et al (7) . They reported that antiviral + steroid treatment was dramatically superior to placebo treatment. In addition, our NMA demonstrated that there were no significant differences between the comparisons of antiviral vs placebo and antiviral vs steroid treatments; these conclusions are consistent with our previous study (7) . We also obtained the relative ranking of the 3 therapies from the SUCRA values. Antiviral + steroid treatment was clearly the most satisfactory, with a 90% probability of ranking first and a SUCRA value of 0.96. The efficacies of steroid or antiviral treatments alone were nearly equal, with SUCRA values of 0.54 and 0.36, respectively, and both performed better than placebo therapy, whose SUCRA value was only 0.13.
In conclusion, this NMA provides extensive insight compared with previous works. Our study connected all treatments of facial paralysis from Bell's palsy in a network comparison and obtained a comprehensive ranking of their efficacies in terms of overall recovery. However, due to an insufficient number of related studies in the last several years, we were not able to evaluate the safety of these therapies; this is the major limitation of our study. Further studies should be conducted to provide more evidence for the evaluation of treatments for Bell's palsy. www.painphysicianjournal.com
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